ProShares UltraShort Nasdaq Biotechnology (NASDAQ:BIS) Trading Down 2.4% – Here’s Why

Posted by Kim Johansen on Jan 15th, 2026

ProShares UltraShort Nasdaq Biotechnology (NASDAQ:BIS – Get Free Report)’s share price traded down 2.4% during mid-day trading on Wednesday . The stock traded as low as $9.02 and last traded at $9.02. 25,498 shares changed hands during mid-day trading, an increase of 65% from the average session volume of 15,489 shares. The stock had previously closed at $9.24.

ProShares UltraShort Nasdaq Biotechnology Trading Down 2.4%

The company has a fifty day moving average of $9.62 and a 200 day moving average of $12.49.

ProShares UltraShort Nasdaq Biotechnology Cuts Dividend

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, December 31st. Stockholders of record on Wednesday, December 24th were paid a $0.1026 dividend. This represents a $0.41 dividend on an annualized basis and a dividend yield of 4.5%. The ex-dividend date of this dividend was Wednesday, December 24th.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in ProShares UltraShort Nasdaq Biotechnology stock. Csenge Advisory Group purchased a new position in ProShares UltraShort Nasdaq Biotechnology (NASDAQ:BIS – Free Report) during the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 12,421 shares of the company’s stock, valued at approximately $163,000. Csenge Advisory Group owned approximately 6.54% of ProShares UltraShort Nasdaq Biotechnology at the end of the most recent quarter.

About ProShares UltraShort Nasdaq Biotechnology

(Get Free Report)

ProShares Ultra Nasdaq Biotechnology (the Fund) seeks investment results for a single day only, not for longer periods. The Fund seeks daily investment results, before fees and expenses, that correspond to twice (200%) the daily performance of the Index. The return of the Fund for a period longer than a single trading day will be the result of each day’s returns compounded over the period, which will very likely differ from twice (200%) the return of the Nasdaq Biotechnology Index (the Index) for that period.